Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies

Journal of Clinical Oncology

Volumn 19, Issue 3, 2001, Pages 857-869

  Villalona Calero, M A ^a   Eder, J P ^a   Toppmeyer, D L ^a   Allen, L F ^a   Fram, R ^a   Velagapudi, R ^a   Myers, M ^a   Amato, A ^a   Kagen Hallet, K ^a   Razvillas, B ^a   Kufe, D W ^a   Von Hoff, D D ^a   Rowinsky, E K ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ELINAFIDE; INTERCALATING AGENT; LU 79553; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ERECTILE DYSFUNCTION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MALE; MYOPATHY; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0035253372     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.3.857     Document Type: Article

References (40)

1. Synthesis and mode of action of a new series of imide derivatives of 3-nitro-1,8-naphthalic acid
2. In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC-308847) in human leukemia
3. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs
4. Phase I clinical investigation of amonafide
5. Phase I study of mitonafide in solid tumors
6. Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer
7. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer - A Cancer and Leukemia Group B Study (CALGB 8642)
8. Phase II trial of amonafide for the treatment of advanced, hormonally refractory carcinoma of the prostate. A Southwest Oncology Group study
9. Phase I trial of amonafide + cytosine arabinoside for poor risk acute leukemias
10. Population pharmacodynamic study of amonafide: A Cancer and Leukemia Group B study
11. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender
12. DNA intercalating agents
13. Bisnaphthalimides, synthesis and preclinical evaluation
14. Bis-naphthalimides: A new class of antitumor agents
15. Bisnaphthalimides, synthesis and biological activity of 5,6 acenaphthalimido alkyl-1,8-naphthalimidoalkyl-amines
16. Sequence-selective intercalation of antitumor bis- naphthalimides into DNA. Evidence for an approach via the major groove
17. Preclinical evaluation of LU79553: A novel bisnaphthalamide with potent antitumor activity
18. Bisnaphthalimides 3: Synthesis and antitumor activity of N,N′-bis[2-(1,8-naphthalimido)-ethyl] alkalenediamines
19. LU79553 evaluation by human tumor clonogenic assay of a novel naphthalimide
20. Prediction of creatinine clearance from serum creatinine
21. A phase I study of LU79553 administered every 21 days in patients (PTS) with solid tumors: An EORTC/ECSG study
22. Phase I study of elinafide in solid tumors
23. Choosing among generalized linear models applied to medical data
24. Grading of muscle power: Comparison of MRC and analogue scales by physiotherapists. Medical Research Council
25. Phase I study of mitonafide with a 3-day administration schedule: Early interruption due to severe central nervous system toxicity
26. A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion
27. Risk factors for doxorubicin-induced congestive heart failure
28. A review of cardiac pathology in relation to anthracycline cardiotoxicity
29. Subcellular effects of adriamycin in the heart: A concise review
30. Adriamycin-stimulated hydroxyl radical formation in human breast tumor cells
31. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: Alterations produced by doxorubicin
32. Drugs used in the chemotherapy of amebiasis
33. Emetine toxicity in man: Studies on the nature of early toxic manifestations, their relation to the dose level and their significance in determining safe dosage
34. Reversible myopathy secondary to abuse of ipecac in patients with major eating disorders
35. Cardiac manifestations of toxic action of emetine hydrochloride in amebic dysentery
36. Death resulting from ipecac syrup poisoning
37. Observations on the mechanism of emetine poisoning of myocardial tissue
38. Structural basis for the inhibition of protein synthesis by emetine and cycloheximide based on an analogy between ipecac alkaloids and glutarimide antibiotics